Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Keep Reading →
September 11 - News
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Keep Reading →
September 9 - News
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
September 4 - News
Today, let's look at investing giant Daniel Loeb, founder of the Third Point LLC hedge fund.
Keep Reading →
August 30 - Hedge Funds, News
Shares of Perrigo Company (NYSE:PRGO), one of the world's largest health care suppliers, slid with the broader market on Aug.
Keep Reading →
August 27 - News
Today let's look at investing giant Seth Klarman, who founded the Baupost Group hedge fund company back in 1982. Klarman is a successful investor with a lot to teach us.
Keep Reading →
August 23 - Hedge Funds
Today, let's look at investing giant John Paulson. Founded in 1994 and owned by its employees, Paulson & Co.
Keep Reading →
August 21 - Hedge Funds
Many market-watchers are scratching their heads about the pharmaceutical industry's latest blockbuster deal.
Keep Reading →
August 12 - News
Perrigo Company (NYSE:PRGO)’s acquisition of Elan Corporation, plc (ADR) (NYSE:ELN) for $8.6 billion has been widely criticized by many as a way for Perrigo to avoid paying...
Keep Reading →
August 8 - News
2013 is turning out to be a stellar year for Mergers and Acquisitions. There have been a number of M&A deals in healthcare and technology sectors.
Keep Reading →
August 6 - News
The chances are good that you're a bad investor.
Keep Reading →
August 5 - News
A patented drug is a cash cow for drug manufacturers. There are two ways to have a patented cash generating drug on a pharmaceutical company’s pipeline.
Keep Reading →
August 5 - News
When I interviewed Alkermes Plc (NASDAQ:ALKS)' CEO Richard Pops last year, he described the relocation of the company's headquarters to Ireland where taxes are lower after buying...
Keep Reading →
July 30 - News
After months of fighting off the advances of unwanted suitor Royalty Pharma, Irish biotech Elan Corporation, plc (ADR) (NYSE:ELN) finally got an offer it couldn't refuse -- from...
Keep Reading →
July 29 - News
By now you've probably at least heard of SAC Capital, the massive hedge fund founded and run by the eponymous Steven A. Cohen.
Keep Reading →
July 29 - News
Elan Corporation, plc (ADR) (NYSE:ELN)'s board unanimously rebuffed a $6.7 billion takeover offer from Royalty Pharma in early June and hired Citigroup Inc.
Keep Reading →
July 2 - News
According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion...
Keep Reading →
July 2 - News
The news flow from biotech companies might slow down during the summer, but it won't stop.
Keep Reading →
July 1 - News
Recently Elan Corporation, plc (ADR) (NYSE:ELN)'s shareholders voted against management's proposal to invest $1 billion in Theravance Inc (NASDAQ:THRX), a deal which a fellow...
Keep Reading →
June 18 - News
Elan Corporation, plc (ADR) (NYSE:ELN) has been in the news over the past few months because of a hotly contested battle with Royalty Pharma. The battle began on Feb.
Keep Reading →
June 18 - News
It's understandably very tempting for people with inside information to trade biotech stocks.
Keep Reading →
June 17 - News
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
June 17 - News
The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor.
Keep Reading →
June 17 - News
Seth Klarman's Baupost Group, led by the famed value investor and author of Margin of Safety, recently revealed its public equity portfolio in its quarterly filing with the SEC...
Keep Reading →
May 22 - Hedge Funds
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
May 20 - News
Back towards the end of April 2013, Theravance Inc (NASDAQ:THRX) surprised everyone when it announced plans to split into two separate companies.
Keep Reading →
May 14 - News
Following in the footsteps of Abbott Laboratories (NYSE:ABT) spinning out its drug division into AbbVie Inc (NYSE:ABBV), and Pfizer spinning out its animal health division into...
Keep Reading →
April 26 - News
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Keep Reading →
March 28 - News
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so.
Keep Reading →
March 25 - News
Buying big pharma stocks isn't the only way you can invest in today's best-selling drugs without taking a gamble on a small, risky biotech.
Keep Reading →
March 18 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 7 - News
Elan Corporation, plc (ADR) (NYSE:ELN) was nice enough to give us a little more detail on what it plans to do with the $3.25 million that the biotech stands to get from Biogen...
Keep Reading →
February 25 - News
When Elan Corporation, plc (ADR) (NYSE:ELN) sold its stake in the blockbuster selling multiple sclerosis drug Tysabri to partner Biogen Idec Inc.
Keep Reading →
February 25 - News
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Keep Reading →
February 19 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 18 - News
Elan Corporation, plc (NYSE:ELN) just announced a restructuring of its Tysabri collaboration with Biogen Idec Inc.
Keep Reading →
February 12 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 11 - News
Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion.
Keep Reading →
February 6 - News